Gossamer Bio (GOSS) closed at $11.43 on November 18, 2026, up 3.5% from the previous close, on volume of 239,688 shares (30-day average 196,829).
Data as of November 18, 2026.
18-Nov-2026
Gossamer Bio Announces Third Quarter 2026 Financial Results and Provides Business Update
Business Wire (Tue, 10-Nov 4:01 PM ET)
Business Wire (Wed, 23-Sep 4:01 PM ET)
Gossamer Bio Appoints Greg Ciongoli to Board of Directors
Business Wire (Wed, 16-Sep 4:01 PM ET)
Gossamer Bio Announces Effectiveness of 1-for-80 Reverse Stock Split
Business Wire (Fri, 11-Sep 8:00 AM ET)
Gossamer Bio Announces 1-for-80 Reverse Stock Split
Business Wire (Wed, 9-Sep 9:00 AM ET)
Gossamer Bio to Present at Cantor Global Healthcare Conference
Business Wire (Fri, 4-Sep 8:00 AM ET)
Business Wire (Fri, 21-Aug 8:00 AM ET)
Market Chameleon (Tue, 28-Jul 6:32 AM ET)
Market Chameleon (Mon, 27-Jul 6:30 AM ET)
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension).
Gossamer Bio trades on the NASDAQ stock market under the symbol GOSS.
As of November 18, 2026, GOSS stock price climbed to $11.43 with 239,688 million shares trading.
GOSS has a beta of 2.63, meaning it tends to be more sensitive to market movements. GOSS has a correlation of 0.03 to the broad based SPY ETF.
GOSS has a market cap of $69.84 million. This is considered a Micro Cap stock.
Last quarter Gossamer Bio reported $38 million in Revenue and -$7.36 earnings per share. This beat revenue expectation by $28 million and missed earnings estimates by -$3.10.
In the last 3 years, GOSS traded as high as $309.60 and as low as $8.29.
The top ETF exchange traded funds that GOSS belongs to (by Net Assets): VTI, VXF, IBB, VHT, PRFZ.
GOSS has underperformed the market in the last year with a return of -95.2%, while SPY returned +10.8%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in GOSS shares. However, GOSS has outperformed the market in the last 3 month and 2 week periods, returning +2.1% and +23.2%, while SPY returned -5.3% and -3.2%, respectively. This indicates GOSS has been having a stronger performance recently.
GOSS support price is $10.31 and resistance is $11.77 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GOSS shares will trade within this expected range on the day.